Rapid Dose Therapeutics Corp. (RDTCF)
USD 0.18
(2150.0%)
USD 0.18
(2150.0%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 | -4.3 Million CAD | -13.03% |
| 2023 | -3.81 Million CAD | 55.11% |
| 2022 | -8.48 Million CAD | -269.4% |
| 2021 | -2.29 Million CAD | 71.15% |
| 2020 | -7.96 Million CAD | 30.12% |
| 2019 | -11.39 Million CAD | -22660.73% |
| 2018 | -50.07 Thousand CAD | -6.33% |
| 2017 | -47.09 Thousand CAD | 8.98% |
| 2016 | -51.74 Thousand CAD | -169.47% |
| 2015 | -19.2 Thousand CAD | 1.47% |
| 2014 | -19.48 Thousand CAD | 89.09% |
| 2013 | -178.54 Thousand CAD | -163.66% |
| 2012 | -67.72 Thousand CAD | 15.3% |
| 2011 | -79.95 Thousand CAD | -1074.96% |
| 2010 | -6805.00 CAD | -101.39% |
| 2009 | -3379.00 CAD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q3 | -981.07 Thousand CAD | -34.27% |
| 2024 FY | -4.3 Million CAD | -13.03% |
| 2024 Q4 | -2.05 Million CAD | -109.37% |
| 2024 Q2 | -730.68 Thousand CAD | -28.9% |
| 2024 Q1 | -566.88 Thousand CAD | 56.52% |
| 2023 Q4 | -1.3 Million CAD | -123.42% |
| 2023 Q2 | -914.52 Thousand CAD | 9.31% |
| 2023 Q3 | -583.5 Thousand CAD | 36.2% |
| 2023 Q1 | -1 Million CAD | 86.17% |
| 2023 FY | -3.81 Million CAD | 55.11% |
| 2022 Q3 | -790.75 Thousand CAD | -46.59% |
| 2022 FY | -8.48 Million CAD | -269.4% |
| 2022 Q4 | -7.29 Million CAD | -822.36% |
| 2022 Q1 | 128.62 Thousand CAD | 115.16% |
| 2022 Q2 | -539.43 Thousand CAD | -519.4% |
| 2021 Q3 | -511.8 Thousand CAD | -15.76% |
| 2021 Q1 | -495.24 Thousand CAD | 48.99% |
| 2021 Q4 | -848.47 Thousand CAD | -65.78% |
| 2021 Q2 | -442.11 Thousand CAD | 10.73% |
| 2021 FY | -2.29 Million CAD | 71.15% |
| 2020 Q3 | -3.01 Million CAD | -234.39% |
| 2020 FY | -7.96 Million CAD | 30.12% |
| 2020 Q1 | -3.07 Million CAD | 67.96% |
| 2020 Q2 | -902.66 Thousand CAD | 70.62% |
| 2020 Q4 | -970.79 Thousand CAD | 67.84% |
| 2019 Q4 | -9.58 Million CAD | -853.32% |
| 2019 FY | -11.39 Million CAD | -22660.73% |
| 2019 Q1 | -298.51 Thousand CAD | 75.61% |
| 2019 Q2 | -504.32 Thousand CAD | -68.94% |
| 2019 Q3 | -1 Million CAD | -99.46% |
| 2018 Q3 | -19.44 Thousand CAD | 26.71% |
| 2018 Q1 | -6442.00 CAD | -60.45% |
| 2018 Q2 | -26.53 Thousand CAD | -311.86% |
| 2018 FY | -50.07 Thousand CAD | -6.33% |
| 2018 Q4 | -1.22 Million CAD | -6193.92% |
| 2017 Q4 | -4015.00 CAD | 69.33% |
| 2017 Q3 | -13.09 Thousand CAD | 18.57% |
| 2017 Q2 | -16.07 Thousand CAD | -744.33% |
| 2017 FY | -47.09 Thousand CAD | 8.98% |
| 2017 Q1 | -1904.00 CAD | 88.86% |
| 2016 Q4 | -17.09 Thousand CAD | -42.12% |
| 2016 FY | -51.74 Thousand CAD | -169.47% |
| 2016 Q3 | -12.02 Thousand CAD | 16.14% |
| 2016 Q2 | -14.34 Thousand CAD | -64.82% |
| 2016 Q1 | -8701.00 CAD | -9.3% |
| 2015 FY | -19.2 Thousand CAD | 1.47% |
| 2015 Q3 | -20.74 Thousand CAD | -175.31% |
| 2015 Q2 | 27.54 Thousand CAD | 182.3% |
| 2015 Q1 | -33.46 Thousand CAD | -308.35% |
| 2015 Q4 | -7961.00 CAD | 61.62% |
| 2014 Q2 | -4192.00 CAD | -66.75% |
| 2014 Q3 | -5085.00 CAD | -21.3% |
| 2014 Q4 | -8195.00 CAD | -61.16% |
| 2014 Q1 | -2514.00 CAD | 74.14% |
| 2014 FY | -19.48 Thousand CAD | 89.09% |
| 2013 Q4 | -9723.00 CAD | -217.85% |
| 2013 FY | -178.54 Thousand CAD | -163.66% |
| 2013 Q1 | -32.98 Thousand CAD | -94.83% |
| 2013 Q2 | -123.53 Thousand CAD | -274.54% |
| 2013 Q3 | -3059.00 CAD | 97.52% |
| 2012 Q1 | -7582.00 CAD | 38.6% |
| 2012 Q2 | -36.89 Thousand CAD | -386.65% |
| 2012 Q3 | -5105.00 CAD | 86.16% |
| 2012 Q4 | -16.92 Thousand CAD | -231.62% |
| 2012 FY | -67.72 Thousand CAD | 15.3% |
| 2011 Q3 | -10.89 Thousand CAD | 23.35% |
| 2011 Q4 | -12.34 Thousand CAD | -13.39% |
| 2011 FY | -79.95 Thousand CAD | -1074.96% |
| 2011 Q1 | -7050.00 CAD | 86.91% |
| 2011 Q2 | -14.2 Thousand CAD | -101.53% |
| 2010 Q3 | -4886.00 CAD | -142.0% |
| 2010 Q1 | -1225.00 CAD | 40.1% |
| 2010 FY | -6805.00 CAD | -101.39% |
| 2010 Q4 | -53.86 Thousand CAD | -1002.37% |
| 2010 Q2 | -2019.00 CAD | -64.82% |
| 2009 Q4 | -2045.00 CAD | 54.72% |
| 2009 Q3 | -4516.00 CAD | 0.0% |
| 2009 FY | -3379.00 CAD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Bioxytran, Inc. | -4.28 Million USD | -0.619% |
| Eiger BioPharmaceuticals, Inc. | -74.96 Million USD | 94.255% |
| Institute of Biomedical Research Corp. | -273.4 Thousand USD | -1475.153% |
| SQZ Biotechnologies Company | -79.46 Million USD | 94.581% |
| Intellipharmaceutics International Inc. | -2.89 Million USD | -48.891% |
| Evofem Biosciences, Inc. | 52.97 Million USD | 108.129% |
| Santhera Pharmaceuticals Holding AG | 65.13 Million USD | 106.612% |
| Propanc Biopharma, Inc. | -1.82 Million USD | -136.552% |
| Marizyme, Inc. | -65.34 Million USD | 93.41% |
| Genus plc | 7.9 Million USD | 154.513% |
| Pharming Group N.V. | -10.54 Million USD | 59.172% |
| Therapeutic Solutions International, Inc. | -2.16 Million USD | -98.473% |
| CNBX Pharmaceuticals Inc. | -3.71 Million USD | -16.071% |
| Nymox Pharmaceutical Corporation | -8.84 Million USD | 51.306% |
| ContraFect Corporation | -65.15 Million USD | 93.39% |
| RegeneRx Biopharmaceuticals, Inc. | -1.72 Million USD | -149.297% |
| IMV Inc. | -36.48 Million USD | 88.197% |
| AXIM Biotechnologies, Inc. | -8.05 Million USD | 46.567% |
| ONE Bio Corp. | 8.67 Million USD | 149.633% |
| RVL Pharmaceuticals plc | -51.69 Million USD | 91.669% |
| Mesoblast Limited | -87.95 Million USD | 95.104% |
| MultiCell Technologies, Inc. | -380.07 USD | -1132980.748% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| Emmaus Life Sciences, Inc. | -3.73 Million USD | -15.363% |
| Genscript Biotech Corporation | -95.47 Million USD | 95.489% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -580.97% |
| Mosaic ImmunoEngineering Inc. | -2.38 Million USD | -80.879% |
| Nanobac Pharmaceuticals, Incorporated | -6.57 Million USD | 34.513% |
| Biomind Labs Inc. | -1.21 Million USD | -254.643% |
| Provectus Biopharmaceuticals, Inc. | -3.1 Million USD | -38.84% |
| Oncotelic Therapeutics, Inc. | -7.9 Million USD | 45.509% |
| Skye Bioscience, Inc. | -37.64 Million USD | 88.56% |
| GlobeStar Therapeutics Corporation | -1.94 Million USD | -120.931% |
| VioQuest Pharmaceuticals, Inc. | -10.89 Million USD | 60.461% |
| THC Farmaceuticals, Inc. | -14.97 Thousand USD | -28656.01% |
| PsyBio Therapeutics Corp. | -4.88 Million USD | 11.862% |
| Arch Therapeutics, Inc. | -6.98 Million USD | 38.327% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| Acro Biomedical Co., Ltd. | -15.87 Million USD | 72.866% |
| Accustem Sciences Inc. | -3.74 Million USD | -14.95% |
| EV Biologics, Inc. | -1.26 Million USD | -239.861% |
| Q BioMed Inc. | -2.05 Million USD | -109.859% |
| GB Sciences, Inc. | -1.36 Million USD | -216.264% |
| Alpha Cognition Inc. | -13.77 Million USD | 68.731% |
| CSL Limited | 2.64 Billion USD | 100.163% |
| Agentix Corp. | -1.37 Million USD | -213.38% |
| American Oriental Bioengineering, Inc. | -59.72 Million USD | 92.789% |
| Enzolytics Inc. | -2.17 Million USD | -97.833% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Resverlogix Corp. | -3.61 Million USD | -19.294% |
| Nuo Therapeutics, Inc. | -3.17 Million USD | -35.79% |
| MetaStat, Inc. | - USD | Infinity% |
| Curative Biotechnology, Inc. | -5.81 Million USD | 25.97% |
| argenx SE | -295.05 Million USD | 98.54% |
| Northwest Biotherapeutics, Inc. | -62.59 Million USD | 93.12% |
| HST Global, Inc. | -146.21 Thousand USD | -2845.421% |
| Enzon Pharmaceuticals, Inc. | 98 Thousand USD | 4494.388% |
| Wesana Health Holdings Inc. | -1.75 Million USD | -145.417% |
| Halberd Corporation | -79.67 Thousand USD | -5305.015% |
| Endonovo Therapeutics, Inc. | 6.92 Million USD | 162.191% |
| Inhibitor Therapeutics, Inc. | -3.02 Million USD | -42.31% |
| Zenith Capital Corp. | -10.59 Million USD | 59.357% |
| RespireRx Pharmaceuticals Inc. | -3.97 Million USD | -8.394% |
| GeneThera, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -4.14 Million USD | -3.873% |
| AVAX Technologies, Inc. | -6.41 Million USD | 32.854% |
| WPD Pharmaceuticals Inc. | -60.44 Thousand USD | -7025.176% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -114.776% |
| Ember Therapeutics, Inc. | -23.24 Thousand USD | -18428.956% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Adynxx, Inc. | - USD | Infinity% |
| NovAccess Global Inc. | -4.76 Million USD | 9.702% |
| Helix BioMedix, Inc. | -1.05 Million USD | -307.79% |
| Capstone Therapeutics Corp. | -3.81 Million USD | -12.765% |
| Kadimastem Ltd | -3.3 Million USD | -30.208% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| BioStem Technologies, Inc. | -8.48 Million USD | 49.234% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -441.36 Thousand USD | -875.714% |
| Burzynski Research Institute, Inc. | -1.33 Million USD | -222.48% |
| LadRx Corporation | 400.44 Thousand USD | 1175.434% |
| Cell Source, Inc. | -5.32 Million USD | 19.069% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -936.514% |
| Regen BioPharma, Inc. | 1.02 Million USD | 520.759% |
| Regen BioPharma, Inc. | 1.02 Million USD | 520.759% |
| Affymax, Inc. | -14.42 Million USD | 70.144% |
| Mobile Lads Corp. | -2.26 Million USD | -90.276% |
| Itoco Inc. | -1.86 Million USD | -130.418% |
| Rasna Therapeutics, Inc. | -4.44 Million USD | 3.062% |
| Pathfinder Cell Therapy, Inc. | -1.66 Million USD | -158.029% |
| International Stem Cell Corporation | -131 Thousand USD | -3187.405% |
| CytoDyn Inc. | -49.84 Million USD | 91.36% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.03 Thousand USD | -5348.99% |
| NanoSphere Health Sciences Inc. | -228.12 Thousand USD | -1787.764% |
| Qrons Inc. | -789.34 Thousand USD | -445.578% |
| Alseres Pharmaceuticals, Inc. | -941.52 Thousand USD | -357.394% |
| SYBLEU INC | -180.3 Thousand USD | -2288.466% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | -2.08 Million USD | -106.281% |
| Rebus Holdings, Inc. | -1.02 Million USD | -322.206% |
| GlobeImmune, Inc. | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.61 Million USD | -167.031% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -54.27 Thousand USD | -7835.031% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.53 Million USD | -70.201% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -48.07 Million USD | 91.042% |
| Adhera Therapeutics, Inc. | -2.11 Million USD | -103.713% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -780.88 Thousand USD | -451.488% |
| Innovation Pharmaceuticals Inc. | -3.16 Million USD | -35.938% |
| Neutra Corp. | -233.46 Thousand USD | -1744.602% |
| Windtree Therapeutics, Inc. | -20.29 Million USD | 78.776% |
| PureTech Health plc | -65.69 Million USD | 93.445% |
| Coeptis Therapeutics, Inc. | -21.26 Million USD | 79.75% |
| IXICO plc | -1.17 Million USD | -265.577% |
| IntelGenx Technologies Corp. | -9.92 Million USD | 56.618% |
| Gelesis Holdings, Inc. | -57.12 Million USD | 92.462% |
| CSL Limited | 2.64 Billion USD | 100.163% |
| Cellectis S.A. | -103.17 Million USD | 95.826% |